Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

NCT05652868 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

227

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

NSCLC
NSCLC Stage IV
NSCLC Stage IIIB
Non-Small Cell Lung Cancer
Advanced Non-Small Cell Squamous Lung Cancer
Advanced Non-Small Cell Lung Cancer
Advanced Non-Small Cell Non-Squamous Lung Cancer

Interventions

DRUG: MYTX-011

Sponsor

Mythic Therapeutics